Congenital hyperinsulinism is a rare genetic disorder characterized by excess insulin secretion from pancreatic β-cells that results in recurrent and severe episodes of hypoglycemia. The condition occurs as a result of mutations in genes that regulate insulin secretion. Some key signs and symptoms include low blood sugar, fainting or loss of consciousness, seizures, sweating, trembling, irritability, crying excessively in infants and young children. Congenital hyperinsulinism can be managed using medications such as diazoxide and octreotide to suppress insulin secretion. In severe cases, pancreatectomy or partial pancreatectomy may be advised to remove the insulin-secreting portion of the pancreas. Advancements in surgical techniques and drug interventions have improved clinical outcomes for patients.
The global congenital hyperinsulinism treatment market is estimated to be valued at US$ 217.74 Mn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Rising prevalence of congenital hyperinsulinism is expected to drive the growth of the market during the forecast period. Congenital hyperinsulinism is one of the most common cause of persistent hypoglycemia in neonates and infants with an incidence of 1 in 50,000 live births. According to the European Society for Paediatric Endocrinology, the prevalence rate of congenital hyperinsulinism ranges between 1 in 40,000 to 1 in 50,000 live births. With increasing awareness about the condition and availability of newer treatment options, more cases are being diagnosed early which is expected to increase the demand for disease management drugs and therapies over the coming years.
Another major driver for the market growth is the approval and launch of newer drugs for congenital hyperinsulinism treatment. For instance, in 2018, US FDA approved diazoxide choline extended-release (Proglycem) tablets, an extended-release dosage form of diazoxide, for the treatment of congenital hyperinsulinism in patients 2 months of age and older. Introduction of such innovative treatment therapies are expanding the treatment landscape which is positively impacting the market growth.
The global congenital hyperinsulinism treatment market is dominated by the drug therapy segment accounting for nearly 70% market share. This segment is dominating as drugs are the first line of treatment for congenital hyperinsulinism and have lesser risks associated than surgery. The drug therapy segment is further divided into diazoxide, octreotide, verapamil, glucagon, somatostatin analogs and others. Among these, the diazoxide sub-segment holds the largest market share due to its wide usage in management of congenital hyperinsulinism.
Political: Healthcare reforms in many countries are focusing on rare disease treatment which is boosting public funding for congenital hyperinsulinism treatment.
Economic: Rising healthcare expenditures and growing focus on patient care is positively impacting the market growth.
Social: Increasing awareness about early diagnosis and treatment of congenital hyperinsulinism through patient support organizations is benefiting the market.
Technological: Advancements in drug delivery techniques and focus on customized treatment solutions are expected to offer new opportunities over the forecast period.
The Global Congenital Hyperinsulinism Treatment Market Size is expected to witness high growth at a CAGR of 6.2% during the forecast period of 2023 to 2030.
Regional analysis: The North America region currently dominates the global market owing to developed healthcare infrastructure and rising incidence of congenital hyperinsulinism in the region.
Key players operating in the congenital hyperinsulinism treatment market are Medtronic, Ace-medical, VOGT MEDICAL, BD (Becton, Dickinson and Company), Smiths Medical, Inc., Samtronic., CODAN ARGUS AG, B. Braun SE, Medical Components, Inc., Fresenius SE & Co. KGaA, Baxter, EuroLife Healthcare Pvt. Ltd, and Micrel Medical Devices.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it